<h2>Today ABG Sundal Collier sponsored research initiates coverage of Ascelia Pharma. Read the full report <a href="/link/2495d3ec85384387be75302ee5e89364.aspx"><span style="text-decoration: underline;"><span style="color: #0000ff; text-decoration: underline;">here!</span></span></a></h2> <hr /> <h2>Improving cancer contrast</h2> <hr /> <p><img src="/link/30e9235242f14d17b5c4b78aed503dac.aspx" alt="example_picture" width="500" height="194" /></p> <hr /> <p>Ascelia Pharma is a Swedish biopharma company listed on the Nasdaq Stockholm main market since March 2019. The company is focused on the development of a novel non-gadolinium based MRI contrast agent for the detection of liver metastases in cancer patients with impaired kidney function. The product Orviglance has successfully completed clinical Ph 3 (SPARKLE) in 2024 and is now in preparations towards submission of a NDA to the US FDA by mid'25. The second pipeline candidate Oncoral (novel chemotherapy formulation for gastric cancer) completed Ph 1 successfully and is Ph 2-ready.</p> <hr /> <p><img src="/link/25056fa99dd0432a8797e6130835c5b3.aspx" alt="" width="500" height="1050" /></p>